Results 101 to 110 of about 13,898 (207)

ILAE dietary treatments task force special report: Maternal ketogenic diet exposure in epilepsy pregnancy registries—A call to action

Epilepsia Open, Volume 11, Issue 3, Page 702-709, June 2026.
Abstract Ketogenic dietary therapies (KDTs) are increasingly used worldwide as a non‐pharmacological treatment for epilepsy, including among people of childbearing potential. In many cases, KDTs allow for the reduction of antiseizure medications (ASMs) and lower drug exposure during pregnancy.
Magnhild Kverneland, Valentina De Giorgis, Laura Healy, Kelly Faltersack, Tanya J. W. McDonald, Marisa Armeno, Mackenzie C. Cervenka, Anita Devlin   +7 more
wiley   +1 more source

Plasma and milk metabolomics profiles in dairy cows with subclinical and clinical ketosis

Journal of Dairy Science
Ketosis, a commonly observed energy metabolism disorder in dairy cows during the peripartal period, is distinguished by increased concentrations of BHB in the blood. This condition has a negative impact on milk production and quality, causing financial losses. An untargeted metabolomics approach was performed on plasma samples from cows between 5 and 7
Yan Huang, Bihong Zhang, John Mauck, Juan J. Loor, Bo Wei, Bingyu Shen, Yazhou Wang, Chenxu Zhao, Xiaoyan Zhu, Jianguo Wang   +9 more
openaire   +2 more sources

Energy metabolism, adenosine, and glutamate signaling reprogramming by decanoic acid in Glut1 disorder syndrome

Epilepsia Open, Volume 11, Issue 3, Page 1036-1045, June 2026.
Abstract Glut1 deficiency syndrome (Glut1DS) leads to neurological and cognitive symptoms and is primarily treated using carbohydrate‐restricted ketogenic diets. However, a recent clinical trial of a less restrictive, non‐ketogenic, medium chain triglyceride (MCT) diet with a high decanoic acid content suggests efficacy in Glut1DS treatment.
Erwann Pain, Yatra Kapatel, Pankaj K. Singh, Katie Lloyd Jones, Jamuna Selvakumaran, Alberto Malerba, Walter Lucchesi, Tricia Rutherford, Christina A. Gurnett, Matthew C. Walker, Robin S. B. Williams   +10 more
wiley   +1 more source

Exacerbated Hepatic Stress and Systemic Metabolic Disruption Driven by SARS‐CoV‐2 P.1 Variant in K18‐hACE2 Mice

Immunity, Inflammation and Disease, Volume 14, Issue 6, June 2026.
ABSTRACT Introduction While severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been extensively studied in the context of pulmonary disease, its impact on metabolic organs remains poorly understood, particularly across experimental models.
Monara Kaélle Sérvulo Cruz Angelim, Patrícia Brito Rodrigues, Antônio Thiago Pereira Campos, Giovanni Freitas Gome, Gabriela Fabiano Souza, Valquíria Aparecida Matheus, Carlos Lenz Cesar, José Luiz Proença‐Módena, Marco Aurélio R. Vinolo, Pedro M. Moraes‐Vieira   +9 more
wiley   +1 more source

Clinical ketosis and standing behaviour in transition dairy cows

, 2014
Ketosis is a common disease in dairy cattle, especially in the days after calving, and is often undiagnosed. The objective of this study was to compare the standing behaviour of dairy cows with and without ketosis during the days around calving to determine if changes in this behaviour could be useful in the early identification of sick cows.
openaire   +1 more source

Feline diabetes. Part 2: monitoring and management with other diseases

In Practice, Volume 48, Issue 5, Page 228-241, June 2026.
Background: Diabetes mellitus (DM) in cats is commonly seen in primary care practice and presents several clinical and practical challenges to owners and vets. In recent years feline DM has seen paradigm shifts in management and monitoring. Aim of the article: In this second article of a series on feline DM, we look at the monitoring options that are ...
Ian Ramsey, Anna Kraemer
wiley   +1 more source

Clinical Insights Into the Mechanistic Crossroads of Lamotrigine and Therapeutic Ketosis in Bipolar Depression

Biological Psychiatry Global Open Science
There are substantial care gaps in optimizing treatment response for bipolar depression given, at best, a modicum of benefit from antidepressant treatment and, in contrast, a substantial cardiometabolic burden associated with regulatory-approved antipsychotic treatment.
Dina N. Ali, Iain H. Campbell, Jonathan G. Leung, Tamahara Gonzalez Campos, Duan Liu, Mete Ercis, Matej Markota, Deniz Ceylan, Kyla Lara-Breitinger, Francisco Lopez-Jimenez, Adam S. Anderson, Aysegul Ozerdem, Stacey J. Winham, Mark A. Frye   +13 more
openaire   +2 more sources

Genetics of Response to Canagliflozin (GRC) Study: Rationale, Design, and Pharmacodynamic Responses

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Sodium glucose cotransporter‐2 (SGLT2) inhibitors are a class of antidiabetics with benefits including HbA1c‐lowering, weight loss, cardiovascular and renal protection in addition to adverse effects including genitourinary tract infections, ketoacidosis, and bone loss.
May E. Montasser, Salma A. Bargal, Elizabeth A. Streeten, Hilary B. Whitlatch, Zhinous Shahidzadeh Yazdi, Jordin Sirody, Rosanna Kiplagat, Merna Beshara, Jeffrey R. O’Connell, Simeon I. Taylor, Amber L. Beitelshees   +10 more
wiley   +1 more source

Clinically significant hypoglycaemia in hospitalised adults: A multicentre study of 1205 episodes in the United Kingdom

Diabetic Medicine, Volume 43, Issue 6, June 2026.
Abstract Introduction and Objectives Inpatient hypoglycaemia is a serious complication of diabetes therapy, yet real‐world data on clinically significant episodes remain limited. The objectives of this study are (1) to describe the clinical and biochemical characteristics of clinically significant inpatient hypoglycaemia across multiple NHS sites, (2 ...
Charles Page, Mariam Idrissi, Sam Sherratt‐Mayhew, Aashritha Buchipudi, Amanda Ling Jie Yee, Kalyaani Persad, Aqeelah Khatoon, Amrit Rakkar, Amynta Arshad, Alexandra Lubina Solomon, Rajeev Raghavan, Lakshmi Rengarajan, Ahmed Iqbal, Pratik Choudhary, Aspasia Manta, Punith Kempegowda, DEVI Collaboration   +16 more
wiley   +1 more source

Interrelationship Between Baseline HbA1c, SGLT‐2 Inhibitor Use and Risk of Diabetic Ketoacidosis in Adults With Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5217-5228, June 2026.
ABSTRACT Aims There is ongoing uncertainty about whether initiating sodium–glucose co‐transporter 2 inhibitor (SGLT‐2i) therapy in individuals with type 2 diabetes (T2D) who have elevated baseline HbA1c levels may lead to an additive or potentially synergistic increase in the risk of diabetic ketoacidosis (DKA). This systematic review and meta‐analysis
Samuel Seidu, Setor K. Kunutsor, Erwin Taguiam, Kamlesh Khunti   +3 more
wiley   +1 more source